Macrocyclic Ether Solid Forms for TRK-Sparing ROS1 and ALK Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ROS1-positive or ALK-positive cancers, particularly in the CNS, are associated with adverse reactions such as dizziness, ataxia, paraesthesia, weight gain, and cognitive changes due to TRK inhibition, and there is a need for CNS-penetrant and TRK-sparing inhibitors to address resistance mutations. Additionally, there is a need for a scalable and efficient process to produce ROS1 and ALK inhibitors suitable for human use.
Innovation Solution
Development of crystalline and amorphous forms of heteroaromatic macrocyclic ether compounds, including free bases and salts, which serve as ROS1 and ALK inhibitors, along with methods for their preparation and pharmaceutical compositions that include these forms, to treat cancer effectively while minimizing adverse reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prior art agents are used to treat ROS1-positive or ALK-positive cancer patients, then cancer treatment is achieved, but adverse reactions occur particularly in the central nervous system
Solution Approach 1:
The patent applies local quality by designing the compound to have selective kinase inhibition properties - it specifically inhibits ROS1 and ALK kinases while sparing TRK kinases. This selective action allows the drug to target cancer cells expressing ROS1 or ALK fusions without affecting TRK-mediated normal physiological functions in the CNS, thereby reducing adverse reactions while maintaining cancer treatment efficacy
Solution Approach 2:
The patent inverts the conventional approach by designing a TRK-sparing inhibitor rather than a broad-spectrum kinase inhibitor. Instead of blocking all related kinases and accepting CNS side effects, the invention selectively spares TRK kinases while inhibiting ROS1 and ALK, reversing the traditional trade-off between efficacy and safety
2Reliability
If prior art agents are used to treat ROS1-positive or ALK-positive cancer patients, then cancer treatment is achieved, but inadequate activity against resistance mutations occurs
Solution Approach 1:
The patent applies parameter changes by optimizing the chemical structure of the compound to achieve broader kinase inhibition coverage. The specific molecular structure (Formula I) is designed to interact with multiple kinase domains including mutant forms, allowing the drug to maintain efficacy against various resistance mutations such as G2032R, D2033N, and other ROS1/ALK resistance mutations that confer resistance to prior art agents
3Manufacturing precision
If solid forms of the compound are prepared for pharmaceutical use, then consistent API production is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-characterizing multiple solid forms (crystalline forms I-VI and amorphous form) of the compound with respect to their physicochemical properties, stability, and bioavailability. This preliminary characterization allows the selection of the most suitable solid form for commercial manufacturing, ensuring consistent API production while simplifying the manufacturing process by avoiding the need to develop and qualify multiple forms during production
Data Source
AI summary
Provided herein are solid forms comprising a compound of formula (I), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing a compound of formula (I), pharmaceutical compositions comprising the same, and methods of treating, preventing, and managing various disorders using the compositions provided herein.